Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HES 6% 130/0.4 on Renal Function After Cardiac Surgery
NCT02306213Completed
- Start
- Jan 2011
- Primary completion
- Apr 2013
- Modality
- Polymer-based Nanoparticles, Lipid-based Nanoparticles, Small Molecules
01
Overview
Open-label trial of hetastarch in hypovolemia. Primary endpoint: Renal dysfunction based on RIFLE criteria at 45 days. Started Jan 2011; status: completed.
02
Drugs
hetastarch
03
Conditions
hypovolemia
Beyond the preview
Go deeper on NCT02306213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02306213.